Plasma Neutrophil Gelatinase Associated Lipocalin Levels During Emergency Management of Rhabdomyolysis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01544231|
Recruitment Status : Completed
First Posted : March 5, 2012
Last Update Posted : December 14, 2015
|Condition or disease||Intervention/treatment|
|Rhabdomyolysis Acute Kidney Failure||Biological: Plasma NGAL level|
The secondary objectives of this are:
- to study plasma NGAL levels on admission to the emergency ward as a marker of morbidity and mortality by considering the following factors: duration of hospitalization, need for extracorporeal blood purification, ICU admission, death.
- to study the delay between the onset of the proposed cause of rhabdomyolysis and treatment initiation
- to study the delay between treatment initiation and the occurrence of ARF.
|Study Type :||Observational|
|Actual Enrollment :||197 participants|
|Official Title:||Plasma Neutrophil Gelatinase Associated Lipocalin (NGAL) Levels During Emergency Management of Rhabdomyolysis: Predicting Renal Failure|
|Study Start Date :||August 2013|
|Actual Primary Completion Date :||December 2015|
|Actual Study Completion Date :||December 2015|
Adult patients with suspected rhabdomyolysis admitted to the participating University Hospital emergency rooms (see inclusion/exclusion criteria).
Biological: Plasma NGAL level
The plasmatic level of Neutrophil Gelatinase Associated Lipocalin is measured in ng/ml/
- Plasma NGAL level [ Time Frame: Admittance to the ermergency room (ie at baseline) ]ng/ml
- Delay between initiation of treatment and beginning of acute renal failure [ Time Frame: Day 2 ]meaured in hours
- Delay between cause and treatment [ Time Frame: Day 2 ]Hours elapsed between proposed cause of rhabdomyolysis and treatment initiation measured in hours.
- Need for extracorporeal blood purification [ Time Frame: Hospital discharge (expected average of 2-3 days) ]yes/no
- Patient admitted to ICU? [ Time Frame: Hospital discharge (expected average of 2-3 days) ]yes/no
- Length of hospitalization [ Time Frame: Hospital discharge (expected average of 2-3 days) ]measured in days
- Patient deceased during hospitalization [ Time Frame: Hospital discharge (expected average of 2-3 days) ]yes/no
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01544231
|CHU de Nîmes - Hôpital Universitaire Carémeau|
|Nîmes Cedex 09, Gard, France, 30029|
|CHU de Montpellier - Hôpital Lapeyronie|
|Montpellier, France, 34295|
|CHU de Nice - Hôpital St-Roch|
|Nice, France, 06006|
|APHP - Groupe Hospitalier Pitié-Salpetrière|
|Paris Cedex 13, France, 75651|
|Hôpital Interarmées Sainte Anne|
|Toulon, France, 83800|
|Principal Investigator:||Stéphane Pommet, MD||Centre Hospitalier Universitaire de Nîmes|